Physician profile

Gary E Feldman

Primary Podiatric Medicine · Bethesda, MD

NPI 1891717377

$4,601.56

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$18.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Arthrex, INC. $2,000.00 2019
Supreme Orthopedic Systems, LLC $1,759.05 2019-2021
Zimmer Biomet Holdings, INC. $379.53 2019-2020
Ossio INC $156.15 2021
Acumed LLC $141.75 2021
Wright Medical Technology, INC. $46.28 2020
Stryker Corporation $45.50 2019-2022
Smith+Nephew, INC. $38.38 2019-2024 Memofix Super Elastic Nitinol Staple System, Evos
Horizon Therapeutics Plc $19.08 2019
Bioventus LLC $15.84 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary E Feldman

$4,601.56

in general payments reported 2019-2025

Years
2019-2024
Top company
Arthrex, INC.

https://glasscript.com/doctor/358482/gary-e-feldman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.